Regulatory HHS appoints permanent FDA CBER, CDER heads Pharmaceutical TechnologyThe HHS appoints these leadership positions as it looks to "reform" the FDA, which has recently faced a high turnover in leadership.Read full story pharminent September 10, 2026 (Last updated: September 10, 2026) Pharmaceutical Technology The HHS appoints these leadership positions as it looks to “reform” the FDA, which has recently faced a high turnover in leadership. Read full story Post navigation Previous: FDA Names Permanent CDER and CBER Directors While the Commissioner’s Post Awaits Confirmation Related Stories Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026 Regulatory Ionis nets Zanvastro US approval in first for Alexander disease pharminent September 4, 2026 Regulatory FDA OKs Takeda, Protagonist drug for rare blood cancer pharminent August 31, 2026